Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?
Open accessAbstract
TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.
AI snapshot
Written from the paper’s full text.
TL;DR
This review proposes that the obesity paradox in hypertension may be explained by differing sympathetic nervous system activation phenotypes: normal-weight essential hypertension has a more toxic cardiac sympathetic profile, whereas obesity-hypertension largely lacks these cardiac abnormalities despite shared renal sympathetic activation. It argues this neural difference may outweigh metabolic risk in obesity-hypertension and has implications for antihypertensive drug choice.
Key findings
- In cited hypertension cohorts, overweight/obese patients had lower mortality or cardiovascular events than normal-weight patients: Barrett-Connor and Khaw’s 1727 men aged 50 to 79 years, and INVEST’s 22 576 hypertensive patients with coronary artery disease, in whom class I obese patients had the lowest rate of primary outcome and death.
- Sympathetic activation is not uniform: normal-weight essential hypertension shows cardiac sympathetic activation, increased single-fiber firing rate with salvos, impaired neuronal norepinephrine reuptake (cardiac tritiated norepinephrine extraction 65% vs 81% in controls, P<0.03; tritiated DHPG 992 vs 4588 dpm/min, P<0.01), and sympathetic nerve epinephrine corelease (outward flux averaging 2 ng/min, 5% to 15% of accompanying neuronal norepinephrine release). Obesity-hypertension lacks these: cardiac sympathetic activity is normal or low, single fibers are recruited at a normal firing rate without salvos, reuptake is normal, and epinephrine corelease is absent.
- Both lean and obese essential hypertension share renal sympathetic activation: renal norepinephrine spillover is doubled in milder essential hypertension and trebled in resistant hypertension; renal denervation lowers blood pressure similarly across BMI.
- The authors hypothesize that the toxic sympathetic phenotype cluster in normal-weight hypertension may explain the obesity paradox, and suggest antiadrenergic antihypertensive drugs may be preferred in normal-weight hypertension while diuretics may be preferred in obesity-hypertension.
Methods
- Narrative review and hypothesis paper, not a new primary study; it synthesizes the authors’ prior work and cited literature.
- Data source: over 3 decades of catecholamine isotope dilution and sympathetic nerve recording methodologies in untreated lean and obese patients with essential hypertension, plus cited trials and cohorts.
- Main analysis: qualitative synthesis of organ-specific norepinephrine spillover, clinical microneurography single-fiber firing, cardiac norepinephrine reuptake, and epinephrine cotransmission to contrast sympathetic phenotypes.
Limitations
- Stated in the paper: metabolic and other potential mechanisms “have not been tested for”; causality “can only be inferred”; epinephrine cotransmission is “probable but not proven” and its toxicity “has not been directly proven”; CNS origins of the phenotypes “remain largely obscure”; some mechanisms have not been directly tested in human hypertension.
- Evident from the text: this is a narrative review without systematic search, formal quality assessment, or meta-analysis; it relies on selected prior studies and the authors’ database and presents no new outcome data to directly test the proposed mechanism.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 80 cited sources checked · 0 supported · 0 flagged
- Findingcitation
The outward epinephrine flux averaged 2 ng/min in normal-weight essential hypertension, equivalent to 5% to 15% of the accompanying neuronal norepinephrine release.
“This outward epinephrine flux, measurable by isotope dilution analogous to the measurement of norepinephrine spillover, averaged 2 ng/min in normal-weight essential hypertension, 41 equivalent to 5% to 15% of the accompanying neuronal norepinephrine release.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [41] source
Not checked in the free run.
- The authors state this as an assumption: The epinephrine is coreleased from cardiac sympathetic nerves along with norepinephrine.
- Findingreasoning
There is a remarkable disparity in sympathetic nervous system biology between normal-weight hypertension and obesity-hypertension.
“When these components of sympathetic activation are considered, there is a remarkable disparity in sympathetic nervous system biology between normal-weight hypertension and obesity-hypertension (Table 1).”
Quote in the paperSubstantial claim - Findingown data
In normal-weight essential hypertension, the epinephrine-specific radioactivity in arterial plasma falls in passage through the heart because of the outward flux of epinephrine into coronary sinus blood.
“The epinephrine-specific radioactivity (ratio of tritiated epinephrine concentration/patient's own epinephrine concentration) in arterial plasma in normal-weight essential hypertension falls in passage through the heart because of the outward flux of epinephrine into coronary sinus blood.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The epinephrine is coreleased from cardiac sympathetic nerves along with norepinephrine.
- Findingcitation
Essential hypertensive patients, lean and obese, both share activation of the sympathetic outflow to the kidneys.
“In contrast, essential hypertensive patients, lean and obese, both share an activation of the sympathetic outflow to the kidneys.24”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
- Findingcitation
Multiunit sympathetic nerve firing is similarly increased in both lean and obese hypertensive patients.
“That multiunit sympathetic nerve firing is similarly increased in both lean and obese hypertensive patients is well known.31,32”
Quote in the paperSubstantial claim0 of 2 sources checked
- Findingown data
Sympathetic nerve epinephrine cotransmission is present in normal-weight essential hypertension only.
“This research did disclose sympathetic nerve epinephrine cotransmission, but in normal-weight essential hypertension only.”
Quote in the paperSubstantial claim - Findingcitation
Phenylethanolamine-N-methyltransferase is not present in the biopsied sympathetic nerves of healthy people.
“Phenylethanolamine-N-methyltransferase is not present in the biopsied sympathetic nerves of healthy people.70”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [70] source
Not checked in the free run.
- Findingown data
In obesity-hypertension, the cardiac epinephrine release abnormality is absent.
“In obesity-hypertension, this abnormality is absent.”
Quote in the paperSubstantial claim - Premisecitation
In 22,576 hypertensive patients with coronary artery disease in the INVEST trial, the primary outcome of death, nonfatal myocardial infarction, and nonfatal stroke was lower in overweight and obese patients than in those with normal weight.
“In 22 576 hypertensive patients with coronary artery disease recruited in the INVEST trial (International Verapamil SR Trandolapril Study), Uretsky et al 5 reported that the primary outcome of death, nonfatal myocardial infarction, and nonfatal stroke was lower in overweight and obese patients than in those with normal weight.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] source
Not checked in the free run.
- Premisecitation
In a post hoc analysis of ALLHAT, after removal of those with BMI <22 kg/m2 and never-smokers, the protective effect of obesity was removed.
“In a post hoc analysis, after removal of those with BMI <22 kg/m 2 and never-smokers, the protective effect of obesity was removed.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Premisecitation
Persisting activation of the sympathetic nervous system can be markedly adverse.
“Persisting activation of the sympathetic nervous system can be markedly adverse.”
Quote in the paperSubstantial claim - Premisecitation
Essential hypertension overall is characterized by ongoing sympathetic nervous system activation.
“Perhaps the same might apply in essential hypertension, which overall is also characterized by ongoing sympathetic nervous system activation.22,23”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
In cardiac failure, the level of elevation of the plasma concentration of norepinephrine predicts reduced longevity.
“A prime example is provided by cardiac failure, where the level of elevation of the plasma concentration of norepinephrine in plasma predicts reduced longevity.18”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] source
Not checked in the free run.
- Premisecitation§ Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?
A paradoxical survival advantage with higher BMI exists in the elderly and in a broad range of illnesses, including diabetes mellitus, chronic heart failure, acute heart failure, coronary artery disease, and percutaneous coronary artery interventions.
“the case is strong that such a paradoxical relation exists in the elderly, 7 and accompanying a broad range of illnesses, including diabetes mellitus, 8 chronic heart failure, 9,10 acute heart failure, 11 coronary artery disease, 12 and percutaneous coronary artery interventions.13”
Quote in the paperSubstantial claim0 of 4 sources checked - Interpretationreasoning
The differences in sympathetic nervous system biology between normal-weight hypertension and obesity-hypertension explain the Obesity Paradox of essential hypertension.
“We propose that these differences explain the Obesity Paradox of essential hypertension.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The existence of an Obesity Paradox in hypertension is taken as given.
- Premisecitation
In an ALLHAT cohort of hypertensive patients without diabetes mellitus or manifest cardiovascular disease at entry, obesity was associated with lower all-cause mortality.
“In an ALLHAT study (The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) cohort of hypertensive patients without diabetes mellitus or manifest cardiovascular disease at entry, obesity was also found to be associated with lower all-cause mortality.15”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
- Interpretationreasoning
Multiple single-fiber firing salvos in normal-weight essential hypertension have potential for harm, particularly when coupled with faulty neuronal reuptake of norepinephrine.
“These have potential for harm, particularly, when coupled with faulty neuronal reuptake of norepinephrine, now to be discussed.”
Quote in the paperSubstantial claim - Premisecitation
In heart failure, patients with the highest cardiac sympathetic activity, measured by cardiac norepinephrine spillover, fared worst.
“When sympathetic activity in heart failure was prospectively measured specifically in the heart using cardiac norepinephrine spillover measurements, patients with the highest cardiac sympathetic activity clearly fared worst.19”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Not checked in the free run.
- Premisecitation
In INVEST, class I obese patients had the lowest rate of primary outcome and death.
“Class I obese patients had the lowest rate of primary outcome and death.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] source
Not checked in the free run.
- Premisecitation
In INVEST, the primary outcome was lower in classes II and III obese patients.
“In addition, the primary outcome was lower in classes II and III obese patients.5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] source
Not checked in the free run.
- Premisecitation
In drug-resistant essential hypertension, renal nerve ablation lowers blood pressure to a similar degree in normal-weight essential hypertension and obesity-hypertension.
“In drug-resistant essential hypertension, renal nerve ablation lowers blood pressure to a similar degree in normalweight essential hypertension and obesity-hypertension. 103”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [103] source
Not checked in the free run.
- Premisecitation
Atrial fibrillation is often initiated by an episode of sympathetic nervous system activation.
“The evidence is strong that atrial fibrillation is often initiated by an episode of sympathetic nervous system activation.50”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
- Premisecitation
Normal-weight essential hypertension and obesity-hypertension share very substantial activation of the renal sympathetic outflow.
“In contrast to these disparate changes in the sympathetic nervous system in the 2 essential hypertension variants, normalweight essential hypertension and obesity-hypertension share in having very substantial activation of the renal sympathetic outflow.24”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
- Premisecitation
On average, renal norepinephrine spillover is doubled in patients with milder essential hypertension, both lean and obese.
“On average, renal norepinephrine spillover is doubled in patients with milder essential hypertension, both lean and obese, 24”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
- Interpretationreasoning
The sympathetic pathophysiology of normal-weight essential hypertension-preferential cardiac sympathetic activation, single-fiber firing salvos, and impaired neuronal reuptake of norepinephrine-provides a fertile field for atrial fibrillation.
“The sympathetic pathophysiology of normalweight essential hypertension, a preferential activation of the cardiac sympathetic outflow, coupled with single-fiber firing salvos and impaired neuronal reuptake of norepinephrine, provides a fertile field for this.”
Quote in the paperNot a substantial claim - Premisecitation
Approximately 95% of norepinephrine released by the sympathetic nerves of the heart is recaptured by neuronal reuptake.
“Approximately 95% of norepinephrine released by the sympathetic nerves of the heart is recaptured by neuronal reuptake.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] source
Not checked in the free run.
- Premisecitation
Cardiac sympathetic activation in heart failure, more extreme than in the other conditions, is a proven lethality factor.
“Cardiac sympathetic activation in heart failure, more extreme than in the other conditions, is a proven lethality factor.19”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Not checked in the free run.
- Premisecitation
Renal sympathetic activation in essential hypertension has been specifically targeted in patients with resistant hypertension by catheter-based renal denervation.
“Renal sympathetic activation in essential hypertension has been specifically targeted in patients with resistant hypertension by catheter-based renal denervation.103”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [103] source
Not checked in the free run.
- Interpretationreasoning
Patients with normal-weight essential hypertension generate higher synaptic norepinephrine concentrations in the heart than are present with obesity-hypertension.
“Patients with normal-weight essential hypertension, who have preferential activation of the cardiac sympathetic outflow, high single sympathetic fiber firing rates, and multiple firings within a cardiac cycle, no doubt generate higher synaptic norepinephrine concentrations in the heart than are present with obesity-hypertension.”
Quote in the paperSubstantial claim - Interpretationreasoning
In normal-weight essential hypertension, the linking of substantial activation of the cardiac sympathetic outflow with single-fiber firing salvos and impairment of neuronal noradrenaline reuptake is adverse.
“In normal-weight essential hypertension, the linking of substantial activation of the cardiac sympathetic outflow with single-fiber firing salvos and impairment of neuronal noradrenaline reuptake no doubt is adverse.”
Quote in the paperSubstantial claim - Interpretationreasoning
Coupling of an uptake defect with nerve firing salvos would increase the risk of toxicity.
“Coupling of an uptake defect with nerve firing salvos would increase the risk of toxicity.”
Quote in the paperSubstantial claim - Premisecitation
Frequent, irregular trains of sympathetic nerve firing lead to greatly heightened postsynaptic stimulation.
“Frequent, irregular trains of sympathetic nerve firing are documented to lead to greatly heightened postsynaptic stimulation.54,55”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationcitation
Ventricular arrhythmias in hypertensive patients with coronary artery stenosis and myocardial ischemia can represent a triggered phenomenon deriving from accentuated high cardiac sympathetic activation accompanying mental stress or strenuous exercise.
“This can represent a triggered phenomenon, deriving from the accentuated, high level of cardiac sympathetic activation accompanying mental stress or strenuous exercise.49,98”
Quote in the paperNot a substantial claim0 of 2 sources checked - Interpretationreasoning
The mechanism by which renal sympathetic activation raises blood pressure in essential hypertension probably involves a rightward shifting of the pressure-natriuresis curve.
“It is probable that the mechanism importantly involves renal tubular reabsorption of sodium, and specifically, a rightward shifting of the pressure-natriuresis curve.”
Quote in the paperSubstantial claim - Interpretationreasoning
Chronic cardiac sympathetic activity is likely adverse, especially when coupled with single sympathetic nerve fiber firing salvos and impaired neuronal norepinephrine reuptake.
“As presented earlier, chronic cardiac sympathetic activity is likely adverse, especially when coupled with single sympathetic nerve fiber firing salvos and impaired neuronal norepinephrine reuptake.”
Quote in the paperSubstantial claim - Premisecitation
Impaired neuronal noradrenaline reuptake, as a solitary identified abnormality in patients with postural tachycardia syndrome, is not associated with heart disease or reduced longevity.
“Impaired neuronal noradrenaline reuptake, as a solitary identified abnormality in patients with the postural tachycardia syndrome, 70,82 is not associated with heart disease or reduced longevity.”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Renal norepinephrine spillover is trebled in resistant hypertension.
“and trebled in resistant hypertension.100”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [100] source
Not checked in the free run.
- Premisecitation
Disposition of norepinephrine after its release is more dependent on neuronal reuptake in the heart than in all other organs.
“Disposition of norepinephrine after its release is more dependent on neuronal reuptake in the heart than in all other organs.45”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] source
Not checked in the free run.
- Premisecitation
In untreated, milder grades of hypertension, blood pressure lowering is achieved with renal denervation across the BMI range.
“In untreated, milder grades of hypertension, again blood pressure lowering is achieved with renal denervation across the BMI range.104”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [104] source
Not checked in the free run.
- Interpretationreasoning
The central nervous system origins of sympathetic nervous activation must differ in lean and obese patients with essential hypertension.
“Given the striking dissimilarities, the central nervous system (CNS) origins of sympathetic nervous activation must differ in lean and obese patients with essential hypertension.”
Quote in the paperNot a substantial claim - Interpretationcitation
For cardiac sympathetic activation, the ranking is cardiac failure > normal-weight essential hypertension > depressive illness > aging.
“The ranking is as follows: for cardiac sympathetic activation, cardiac failure>normal-weight essential hypertension>depressive ill ness>aging.19,22,24,42,44,45,49,78”
Quote in the paperNot a substantial claim0 of 8 sources checked- cites [19] source
Not checked in the free run.
- cites [22] source
Not checked in the free run.
- cites [24] source
Not checked in the free run.
- cites [42] source
Not checked in the free run.
- cites [44] source
Not checked in the free run.
- cites [45] source
Not checked in the free run.
- cites [49] source
Not checked in the free run.
- cites [78]
Not checked in the free run.
- Interpretationreasoning
Renal sympathetic activation contributes importantly to the initiation and maintenance of blood pressure elevation in essential hypertension, in both normal-weight and obesity-hypertension.
“This renal sympathetic activation is important in the initiation and maintenance of the blood pressure elevation in essential hypertension.”
- Also stated in: § Perspectives · plain
“Activation of the renal sympathetic outflow in both obese and normal-weight essential hypertension contributes importantly to the pathogenesis of the hypertension.”
Quote in the paperSubstantial claim - Also stated in: § Perspectives · plain
- Interpretationnone given
The sympathetic activation of obesity-hypertension is not totally innocuous.
“The sympathetic activation of obesity-hypertension, of course, is not totally innocuous.”
Quote in the paperNot a substantial claim - Premisecitation
Neural mechanisms are most likely to generate ventricular arrhythmias when coupled with coronary artery stenosis and myocardial ischemia, which is common in hypertensive patients.
“Neural mechanisms are most likely to generate ventricular arrhythmias when coupled with coronary artery stenosis and myocardial ischemia, common in hypertensive patients.”
Quote in the paperNot a substantial claim0 of 2 sources checked - Interpretationreasoning
Pathological release of epinephrine from the heart most probably represents sympathetic nerve epinephrine cotransmission.
“Pathological release of epinephrine from the heart most probably represents sympathetic nerve epinephrine cotransmission, but it is not possible to be certain about this.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The epinephrine is coreleased from cardiac sympathetic nerves along with norepinephrine.
- Interpretationreasoning
The mechanism by which renal sympathetic activation raises blood pressure in essential hypertension probably importantly involves renal tubular reabsorption of sodium.
“It is probable that the mechanism importantly involves renal tubular reabsorption of sodium, and specifically, a rightward shifting of the pressure-natriuresis curve.”
Quote in the paperSubstantial claim - Premisecitation
Renal sympathetic nerves are distributed to all levels of the nephron.
“Renal sympathetic nerves are distributed to all levels of the nephron.101,102”
Quote in the paperNot a substantial claim0 of 2 sources checked - Interpretationreasoning
A fault in noradrenaline reuptake could potentially lead to cardiac sympathetic overstimulation.
“This finding demonstrates that a fault in noradrenaline reuptake could potentially lead to cardiac sympathetic overstimulation.”
Quote in the paperSubstantial claim - Interpretationreasoning
The two hypertension variants, obese and lean, are not interconvertible.
“The 2 hypertension variants, obese and lean, are not interconvertible.”
Quote in the paperSubstantial claim - Interpretationcitation
The worse diuretic outcome in normal-weight hypertension may be caused by reactive stimulation of the sympathetic and renin-angiotensin systems by diuretic-induced natriuresis.
“It can be argued that this unexpected result was caused by a reactive stimulation of the sympathetic and renin-angiotensin systems by diuretic-induced natriuresis 109 in normal-weight patients, who untreated have reduced plasma volume, 110 in contrast with obesity-hypertension, in whom volume expansion is common.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [109] source
Not checked in the free run.
- Rests on an assumption: Volume expansion is common in obesity-hypertension.
- Premisecitation
In obesity-hypertension, measures of cardiac sympathetic nerve norepinephrine reuptake were entirely normal.
“In obesity-hypertension, these measures of cardiac sympathetic nerve norepinephrine reuptake, not shown in figure, were entirely normal.33”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [33] source
Not checked in the free run.
- Interpretationreasoning
Potentially harmful sympathetic activation phenotypes are present in normal-weight essential hypertension.
“But potentially harmful sympathetic activation phenotypes are present in normal-weight essential hypertension.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Normal-weight essential hypertension must have its own unique origins.
“Normal-weight essential hypertension must have its own unique origins.”
Quote in the paperSubstantial claim - Premisecitation
Untreated normal-weight essential hypertension patients have reduced plasma volume.
“in normal-weight patients, who untreated have reduced plasma volume, 110”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [110] source
Not checked in the free run.
- Premisecitation
In healthy people in youth and middle age, there is obesity risk, not an Obesity Paradox.
“And the final important point to make is this: in healthy people in youth and middle age, there is obesity risk, not an Obesity Paradox.115”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
- Premisecitation
Clinical trial evidence is that β-adrenergic blocking drugs have been less beneficial in hypertension than anticipated.
“Clinical trial evidence is that β-adrenergic blocking drugs have been less beneficial in hypertension than anticipated.106”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [106] source
Not checked in the free run.
- Interpretationcitation
Weight loss in obesity-hypertension is most unlikely to transform the patient into a normal-weight hypertensive patient with the accompanying sympathetic phenotype.
“This is most unlikely, of course.”
Quote in the paperSubstantial claim - Premisecitation
Aging produces impairment of neuronal norepinephrine reuptake.
“In addition, aging produces impairment of neuronal norepinephrine reuptake.90”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [90] source
Not checked in the free run.
- Premisecitation
In hypertensive patients, diuretic treatment produces worse clinical cardiovascular outcomes in lean/normal-weight compared with obese patients at similar blood pressure reduction.
“Conversely, with diuretic administration, normalweight essential hypertension fares worse than obesityhypertension.”
- Also stated in: § Perspectives · plain
“In both studies, reduction achieved in clinical cardiovascular end points, at similar blood pressure reduction, was materially worse with diuretic treatment in lean compared with obese hypertensive patients.”
Quote in the paperSubstantial claim0 of 2 sources checked - Also stated in: § Perspectives · plain
- May combine two claims. 16
- Classified as probably not a substantial claim. 10
May combine two claims.
FindingcitationActivation of the sympathetic outflow to the heart is present in normal-weight essential hypertension only; in obesity-hypertension, cardiac sympathetic activation is absent.
“Activation of the sympathetic outflow to the heart is present in normal-weight essential hypertension only (Figure 1).24 In obesity-hypertension, cardiac sympathetic activation is absent.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
May combine two claims.
FindingcitationNeuronal uptake of norepinephrine is impaired substantially in lean hypertensive patients, but not reduced at all in obesity-hypertension.
“Neuronal uptake of norepinephrine is impaired substantially in lean hypertensive patients, but not reduced at all in obesity-hypertension. 36”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [36] source
Not checked in the free run.
May combine two claims.
FindingcitationIn normal-weight essential hypertension, total spillover of norepinephrine to plasma, a measure of global sympathetic activity, is increased and higher than in obesity-hypertension.
“In normal-weight essential hypertension, the total spillover of norepinephrine to plasma, measured by isotope dilution, a measure of global sympathetic activity, is increased 24 and higher than in obesityhypertension.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
May combine two claims.
FindingcitationIn lean hypertensive patients, the increase in sympathetic activity evident in multiunit burst number and size is because of an increase in the firing rate of individual single fibers and to the common presence of firing salvos, multiple firings in a single cardiac cycle.
“In lean hypertensive patients, the increase in sympathetic activity evident in multiunit burst number and size is because of an increase in the firing rate of individual single fibers, and to the common presence of firing salvos, multiple firings in a single cardiac cycle 31 (Figure 2).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [31] source
Not checked in the free run.
May combine two claims.
Findingnone givenIn obesity-hypertension, single-fiber firing salvos are infrequent, and the single-fiber firing rate is normal.
“Conversely, in obesity-hypertension, single-fiber firing salvos are infrequent, and the single-fiber firing rate is normal.”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationMolecular analyses of sympathetic nerves of hypertensive patients accessed by subcutaneous vein biopsy disclose the presence of the epinephrine-synthesizing enzyme phenylethanolamine-N-methyltransferase, suggesting that epinephrine is synthesized in situ in the nerves.
“Molecular analyses of sympathetic nerves of hypertensive patients accessed by subcutaneous vein biopsy disclose the presence of the epinephrine-synthesizing enzyme phenylethanolamine-N-methyltransferase, 70 suggesting that epinephrine is synthesized in situ in the nerves.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [70] source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based).
Findingnone givenCardiac sympathetic excitation is confined to normal-weight essential hypertension.
“Cardiac sympathetic excitation is confined to normal-weight essential hypertension.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingnone givenCardiac failure, depressive illness, panic disorder, postural tachycardia syndrome, and aging share with normal-weight essential hypertension, to differing degrees, the possession of the sympathetic activation phenotypes; obesity-hypertension has none.
“Cardiac failure, depressive illness, panic disorder, postural tachycardia syndrome, and aging share with normal-weight essential hypertension, to differing degrees, the possession of the sympathetic activation phenotypes.Obesityhypertension has none (Table 2).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataExtraction of tritiated norepinephrine from plasma in cardiac transit was reduced in normal-weight essential hypertension compared with healthy controls, and generation of tritiated DHPG was less.
“The extraction of tritiated norepinephrine from plasma in cardiac transit was reduced in normal-weight essential hypertension (EH) compared with healthy controls (NS), and the generation of tritiated DHPG was less.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Premisecitation§ Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?The relation of BMI to mortality is J shaped, this relationship is not dictated by smoking, and the best (lowest mortality) weight for height increases with age.
“Andres reported that the relation of BMI to mortality was J shaped, this relationship not being dictated by smoking, and that the best (lowest mortality) weight for height increases with age.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Andres 1
Not checked in the free run.
- cites Build study, 2
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationWhole-body DEXA scans demonstrate a clear relationship of BMI to fat mass and fat-free mass.
“Despite these considerations, whole-body DEXA (dual-energy X-ray absorptiometry) scans demonstrate a clear relationship of BMI to fat mass and fat-free mass.17”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [17] source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).
Premisenone given§ Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?No ready explanation of the Obesity Paradox is available.
“Beyond the general premise that it might be helpful to have ample energy reserves available in the form of adipose depots in contexts like these, a not unreasonable proposition, no ready explanation of the Obesity Paradox is available.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationApplying extensive exclusions to the analysis of weight and mortality data is a flawed process.
“Flegal et al 16 have emphasized that applying extensive exclusions to the analysis of weight and mortality data is a flawed process.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [16] source
Not checked in the free run.
May combine two claims.
PremisecitationIn the index study of 1727 men aged 50 to 79 years, age-adjusted all-cause and ischemic heart disease mortality was reduced in overweight and obese men, and this finding remained when those with a history of cigarette smoking were excluded.
“In this index study on 1727 men aged 50 to 79 years, age-adjusted all-cause and ischemic heart disease mortality was reduced in overweight and obese men, a finding which remained when those with a history of cigarette smoking were excluded.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] source
Not checked in the free run.
May combine two claims.
PremisecitationWith the coexistence of impaired norepinephrine reuptake with firing salvos in normal-weight essential hypertension and in depressive illness and panic disorder, there is evidence of cardiac risk, even in panic disorder.
“Conversely, with the coexistence of impaired norepinephrine reuptake with firing salvos in normal-weight essential hypertension 31,[33][34][35][36] and in depressive illness 42,51,79 and panic disorder, 51,79,80 there is evidence of cardiac risk, 84 even in panic disorder.[85][86][87]”
Quote in the paperSubstantial claim0 of 5 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisereasoningEpinephrine has higher affinity for β-adrenoceptors than norepinephrine, so a potential for cardiac arrhythmia generation exists.
“But of interest is the high affinity of epinephrine for β-adrenoceptors, higher than for norepinephrine, so a potential for cardiac arrhythmia generation exists.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
PremisecitationThere is evidence of greater blood pressure lowering with antiadrenergic antihypertensive drugs in patients with obesity-hypertension.
“One view is that in patients with obesity-hypertension, antiadrenergic antihypertensive drugs should be preferentially used; there is evidence of greater blood pressure lowering in them.105”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [105] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationFissuring or rupture of an atherosclerotic plaque commonly is the immediate antecedent to activation of the thrombosis cascade.
“The fissuring or rupture of an atherosclerotic plaque commonly is the immediate antecedent to the activation of the thrombosis cascade.99”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [99] source
Not checked in the free run.
May combine two claims.
InterpretationcitationNerve firing salvos are most likely generated in sympathetic ganglia and are probably represented in multiple regional sympathetic outflows, including the outflow to skeletal muscle vasculature and to the heart.
“The phenomenon of nerve firing salvos, because it is most likely generated in sympathetic ganglia, 52 is probably represented in multiple regional sympathetic outflows, including in the outflow to skeletal muscle vasculature where it can be measured, and to the heart where it can be inferred.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [52] source
Not checked in the free run.
May combine two claims.
InterpretationcitationThe presence of multiple firing salvos in the human heart is probable, because patients who have nerve firing salvos recorded at microneurography have, in parallel, the highest levels of cardiac norepinephrine spillover.
“Direct recording from the human cardiac sympathetic nerves is not possible, but the presence there of multiple firing salvos is probable, as patients who have nerve firing salvos recorded at microneurography have, in parallel, the highest levels of cardiac norepinephrine spillover.51”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [51] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOngoing systemic sympathetic activation has long been thought to be noxious in heart failure and renal failure.
“Ongoing systemic sympathetic activation has long been thought to be noxious, in heart failure 18,19 and renal failure.113”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationA diet producing negative energy balance, with accompanying weight loss, reduces sympathetic activity and lowers blood pressure.
“A diet producing negative energy balance, with accompanying weight loss, reduces sympathetic activity and lowers blood pressure.111,112”
Quote in the paperSubstantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Interpretationnone givenEvaluation of sympathetic activation has usually been imprecise, involving global, generic tests such as plasma norepinephrine measurements.
“But it has not been possible to take this idea further, to the investigation of less extreme cases, because the evaluation of sympathetic activation has usually been imprecise, involving global, generic tests such as plasma norepinephrine measurements.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationAging increases sympathetic activity, evident in higher multiunit sympathetic nerve firing measured by microneurography and in higher cardiac norepinephrine spillover, both at rest and during mental stress.
“Aging does increase sympathetic activity, evident in higher multiunit sympathetic nerve firing measured by microneurography 77 and in higher cardiac norepinephrine spillover, both at rest and during mental stress.90”
Quote in the paperNot a substantial claim0 of 2 sources checked
The authors state this as an assumption.
The existence of an Obesity Paradox in hypertension is taken as given.
“I take the existence of an Obesity Paradox to be disputed, but a given.”
The authors state this as an assumption.
The epinephrine is coreleased from cardiac sympathetic nerves along with norepinephrine.
“The assumption, probable but not proven here, is that the epinephrine is coreleased from cardiac sympathetic nerves along with norepinephrine.”
The paper relies on this without support.
Volume expansion is common in obesity-hypertension.
“in contrast with obesity-hypertension, in whom volume expansion is common.”
The paper relies on this without support.
Metabolic risk is commonly present in obesity-hypertension.
“The thesis is that this risk must outrank the metabolic risk commonly present in obesity-hypertension.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Renal sympathetic nerve activity, assessed by kidney noradrenaline spillover, is higher in individuals with obesity than in those who are non-obese and normotensive.
“RSNA, assessed by kidney noradrenaline spillover, is also higher in individuals with obesity than in those who are non-obese and normotensive152,154.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cardiac epinephrine release in heart failure is described as both neural and nonneural
MinorThe text says reference 39 demonstrated release from sympathetic nerves, but the cited reference's title describes evidence for nonneural release. Those descriptions assign opposing sources to the same reported finding.
“We have previously demonstrated sympathetic nerve epinephrine corelease in the heart of patients with cardiac failure, 39”
“39. Kaye DM, Lefkovits J, Cox H, Lambert G, Jennings G, Turner A, Esler MD. Regional epinephrine kinetics in human heart failure: evi- dence for extra-adrenal, nonneural release.”
Cites
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807 · see citing works
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649 · see citing works
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125 · see citing works
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,331 · see citing works
Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old
Adams, K. F., Schatzkin, A. G., Harris, T. B., Kipnis, V., Mouw, T., Ballard-Barbash, R. R., Hollenbeck, A. R., & Leitzmann, M. F. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055643 · Cited by 2,115 · see citing works
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108 · see citing works
Self-citationDavies, M. J., & Thomas, A. C. (1985) · Heart · doi:10.1136/hrt.53.4.363 · Cited by 1,985 · see citing works
Romero-Corral, A., Montori, V. M., Somers, V. K., Korinek, J., Thomas, R. J., Allison, T. G., Mookadam, F., & Lopez-Jimenez, F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69251-9 · Cited by 1,652 · see citing works
Neural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212 · see citing works
Neural Control of Renal Function*
Kopp, U. C., & DiBona, G. F. (2020) · Reflex Control of the Circulation · doi:10.1201/9780367813338-17 · Cited by 1,126 · see citing works
Hasking, G. J., Esler, M. D., Jennings, G. L., Burton, D., Johns, J. A., & Korner, P. I. (1986) · Circulation · doi:10.1161/01.cir.73.4.615 · Cited by 1,028 · see citing works
Self-citationThe Obesity Paradox: Body Mass Index and Outcomes in Patients With Heart Failure
Curtis, J. P., Selter, J. G., Wang, Y., Rathore, S. S., Jovin, I. S., Jadbabaie, F., Kosiborod, M., Portnay, E. L., Sokol, S. I., Bader, F., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.1.55 · Cited by 809 · see citing works
Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions
Esler, M., Jennings, G., Lambert, G., Meredith, I., Horne, M., & Eisenhofer, G. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.4.963 · Cited by 794 · see citing works
Self-citationTownsend, R. R., Mahfoud, F., Kandzari, D. E., Kario, K., Pocock, S., Weber, M. A., Ewen, S., Tsioufis, K., Tousoulis, D., Sharp, A. S. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32281-x · Cited by 752 · see citing works
Rubinshtein, R., Kuvin, J. T., Soffler, M. I., Lennon, R. J., Lavi, S., Nelson, R. E., Pumper, G. M., Lerman, L. O., & Lerman, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq010 · Cited by 683 · see citing works
Adverse consequences of high sympathetic nervous activity in the failing human heart
Kaye, D. M., Lefkovits, J., Jennings, G. L., Bergin, P., Broughton, A., & Esler, M. D. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00332-0 · Cited by 665 · see citing works
Self-citationEsler, M., Jennings, G., Korner, P., Willett, I., Dudley, F., Hasking, G., Anderson, W., & Lambert, G. (1988) · Hypertension · doi:10.1161/01.hyp.11.1.3 · Cited by 642 · see citing works
Self-citationSimpson, P. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111023 · Cited by 618 · see citing works
Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age
Sundlöf, G., & Wallin, B. G. (1978) · The Journal of Physiology · doi:10.1113/jphysiol.1978.sp012170 · Cited by 601 · see citing works
Association of Weight Status With Mortality in Adults With Incident Diabetes
Carnethon, M. R., De Chavez, P. J. D., Biggs, M. L., Lewis, C. E., Pankow, J. S., Bertoni, A. G., Golden, S. H., Liu, K., Mukamal, K. J., Campbell-Jenkins, B., et al. (2012) · JAMA · doi:10.1001/jama.2012.9282 · Cited by 567 · see citing works
Prospective study of phobic anxiety and risk of coronary heart disease in men.
Kawachi, I. I., Colditz, G. A., Ascherio, A., Rimm, E. B., Giovannucci, E. L., Stampfer, M. J., & Willett, W. C. (1994) · Circulation · doi:10.1161/01.cir.89.5.1992 · Cited by 563 · see citing works
Obesity paradox in patients with hypertension and coronary artery disease
Uretsky, S., Messerli, F. H., Bangalore, S., Champion, A., Cooper-DeHoff, R. M., Zhou, Q., & Pepine, C. J. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.05.011 · Cited by 550 · see citing works
Sympathetic Activity in Obese Subjects With and Without Obstructive Sleep Apnea
Narkiewicz, K., van de Borne, P. J. H., Cooley, R. L., Dyken, M. E., & Somers, V. K. (1998) · Circulation · doi:10.1161/01.cir.98.8.772 · Cited by 525 · see citing works
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · see citing works
Fonarow, G. C., Srikanthan, P., Costanzo, M. R., Cintron, G. B., & Lopatin, M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.09.007 · Cited by 512 · see citing works
Body composition and prognosis in chronic systolic heart failure: the obesity paradox
Lavie, C. J., Osman, A. F., Milani, R. V., & Mehra, M. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00031-6 · Cited by 486 · see citing works
Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage
Mancia, G., Grassi, G., Giannattasio, C., & Seravalle, G. (1999) · Hypertension · doi:10.1161/01.hyp.34.4.724 · Cited by 471 · see citing works
Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy
Schlaich, M. P., Kaye, D. M., Lambert, E., Sommerville, M., Socratous, F., & Esler, M. D. (2003) · Circulation · doi:10.1161/01.cir.0000081775.72651.b6 · Cited by 459 · see citing works
Self-citationCardiac Sympathetic Nerve Function in Congestive Heart Failure
Eisenhofer, G., Friberg, P., Rundqvist, B., Quyyumi, A. A., Lambert, G., Kaye, D. M., Kopin, I. J., Goldstein, D. S., & Esler, M. D. (1996) · Circulation · doi:10.1161/01.cir.93.9.1667 · Cited by 453 · see citing works
Self-citationCatecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness
Madden, K. S., Sanders, V. M., & Felten, D. L. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.002221 · Cited by 441 · see citing works
Translational medicine: the antihypertensive effect of renal denervation
DiBona, G. F., & Esler, M. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00647.2009 · Cited by 432 · see citing works
Self-citationMeredith, I. T., Broughton, A., Jennings, G. L., & Esler, M. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108293250905 · Cited by 420 · see citing works
Self-citationPotential clinical relevance of the “little brain” on the mammalian heart
Armour, J. A. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.041178 · Cited by 417 · see citing works
Neural mechanisms in human obesity-related hypertension
Rumantir, M. S., Vaz, M., Jennings, G. L., Collier, G., Kaye, D. M., Seals, D. R., Wiesner, G. H., Brunner-La Rocca, H. P., & Esler, M. D. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917080-00012 · Cited by 396 · see citing works
Self-citationRenal Afferent Denervation Prevents Hypertension in Rats With Chronic Renal Failure
Campese, V. M., & Kogosov, E. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.878 · Cited by 356 · see citing works
Hering, D., Lambert, E. A., Marusic, P., Walton, A. S., Krum, H., Lambert, G. W., Esler, M. D., & Schlaich, M. P. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00194 · Cited by 356 · see citing works
Self-citationSympathetic and Cardiorenal Actions of Leptin
Haynes, W. G., Sivitz, W. I., Morgan, D. A., Walsh, S. A., & Mark, A. L. (1997) · Hypertension · doi:10.1161/01.hyp.30.3.619 · Cited by 348 · see citing works
Baskin, D. G., Figlewicz, D. P., Woods, S. C., Porte, D., & Dorsa, D. M. (1987) · Annual Review of Physiology · doi:10.1146/annurev.ph.49.030187.002003 · Cited by 344 · see citing works
Phobic Anxiety and Risk of Coronary Heart Disease and Sudden Cardiac Death Among Women
Albert, C. M., Chae, C. U., Rexrode, K. M., Manson, J. E., & Kawachi, I. I. (2005) · Circulation · doi:10.1161/01.cir.0000153813.64165.5d · Cited by 330 · see citing works
The Obesity Paradox in the Elderly: Potential Mechanisms and Clinical Implications
Oreopoulos, A., Kalantar-Zadeh, K., Sharma, A. M., & Fonarow, G. C. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.07.005 · Cited by 323 · see citing works
Vollenweider, P., Tappy, L., Randin, D., Schneiter, P., Jéquier, E., Nicod, P., & Scherrer, U. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116542 · Cited by 321 · see citing works
Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics
Shivkumar, K., Ajijola, O. A., Anand, I., Armour, J. A., Chen, P., Esler, M., De Ferrari, G. M., Fishbein, M. C., Goldberger, J. J., Harper, R. M., et al. (2016) · The Journal of Physiology · doi:10.1113/jp271870 · Cited by 308 · see citing works
Self-citationSympathetic activity in major depressive disorder: identifying those at increased cardiac risk?
Barton, D. A., Dawood, T., Lambert, E. A., Esler, M. D., Haikerwal, D., Brenchley, C., Socratous, F., Kaye, D. M., Schlaich, M. P., Hickie, I., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e32829baae7 · Cited by 291 · see citing works
Self-citationInteractions Between Leptin and the Human Sympathetic Nervous System
Eikelis, N., Schlaich, M., Aggarwal, A., Kaye, D., & Esler, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000066289.17754.49 · Cited by 271 · see citing works
Self-citationMeasurement of total and organ-specific norepinephrine kinetics in humans
Esler, M., Jennings, G., Korner, P. I., Blombery, P. A., SACHARIAS, N., & Leonard, P. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.247.1.e21 · Cited by 265 · see citing works
Self-citationGrassi, G., Colombo, M., Seravalle, G., Spaziani, D., & Mancia, G. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.64 · Cited by 256 · see citing works
The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves
Macefield, V. G., Wallin, B. G., & Vallbo, A. B. (1994) · The Journal of Physiology · doi:10.1113/jphysiol.1994.sp020482 · Cited by 248 · see citing works
Cardiovascular Protection Using Beta-Blockers
Bangalore, S., Messerli, F. H., Kostis, J. B., & Pepine, C. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.060 · Cited by 233 · see citing works
Adrenergic Nervous System in Heart Failure
Esler, M., Kaye, D. M., Lambert, G. W., Esler, D., & Jennings, G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00844-8 · Cited by 227 · see citing works
Self-citationFlegal, K. M., Graubard, B. I., Williamson, D. F., & Cooper, R. S. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq341 · Cited by 223 · see citing works
Jannetta, P. J., Segal, R., & Wolfson, S. K. (1985) · Annals of Surgery · doi:10.1097/00000658-198503000-00023 · Cited by 217 · see citing works
Wilkinson, D. J. C., Thompson, J. M., Lambert, G. W., Jennings, G. L., Schwarz, R. G., Jefferys, D., Turner, A. G., & Esler, M. D. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.6.511 · Cited by 214 · see citing works
Self-citationIFN-γ Production by Th1 Cells Generated from Naive CD4+ T Cells Exposed to Norepinephrine
Swanson-Mungerson, M. A., Lee, W. T., & Sanders, V. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.232 · Cited by 207 · see citing works
Mental stress and human cardiovascular disease
Esler, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.011 · Cited by 197 · see citing works
Self-citationDiffering Pattern of Sympathoexcitation in Normal-Weight and Obesity-Related Hypertension
Lambert, E., Straznicky, N., Schlaich, M., Esler, M., Dawood, T., Hotchkin, E., & Lambert, G. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.094649 · Cited by 195 · see citing works
Self-citationImpact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)
Gurm, H. S., Brennan, D. M., Booth, J., Tcheng, J. E., Lincoff, A. M., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02384-6 · Cited by 194 · see citing works
Grassi, G., Seravalle, G., Quarti-Trevano, F., Dell'Oro, R., Arenare, F., Spaziani, D., & Mancia, G. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.121467 · Cited by 194 · see citing works
Obesity-Induced Hypertension: New Concepts From the Emerging Biology of Obesity
Mark, A. L., Correia, M., Morgan, D. A., Shaffer, R. A., & Haynes, W. G. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.537 · Cited by 185 · see citing works
Antihypertensive effect of α- and β-adrenergic blockade in obese and lean hypertensive subjects
Wofford, M. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)01293-6 · Cited by 184 · see citing works
Effects of Aging on the Responsiveness of the Human Cardiac Sympathetic Nerves to Stressors
Esler, M. D., Thompson, J. M., Kaye, D. M., Turner, A. G., Jennings, G. L., Cox, H. S., Lambert, G. W., & Seals, D. R. (1995) · Circulation · doi:10.1161/01.cir.91.2.351 · Cited by 183 · see citing works
Self-citationAging effects on human sympathetic neuronal function
Esler, M., Turner, A., Kaye, D. M., Thompson, J. M., Kingwell, B. A., Morris, M. J., Lambert, G. W., Jennings, G., Cox, H. S., & Seals, D. R. (1995) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1995.268.1.r278 · Cited by 173 · see citing works
Self-citationCHRONIC MENTAL STRESS IS A CAUSE OF ESSENTIAL HYPERTENSION: PRESENCE OF BIOLOGICAL MARKERS OF STRESS
Esler, M., Eikelis, N., Schlaich, M., Lambert, G., Alvarenga, M., Dawood, T., Kaye, D., Barton, D., Pier, C., Guo, L., et al. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04904.x · Cited by 170 · see citing works
Self-citationAssessment of Sympathetic Nervous Function in Humans from Noradrenaline Plasma Kinetics
Esler, M. (1982) · Clinical Science · doi:10.1042/cs0620247 · Cited by 168 · see citing works
Self-citationEsler, M., Jackman, G., Bobik, A., Leonard, P., Kelleher, D., Skews, H., Jennings, G., & Korner, P. (1981) · Hypertension · doi:10.1161/01.hyp.3.2.149 · Cited by 165 · see citing works
Self-citationAbnormalities of Plasma Volume in Borderline Hypertension
Julius, S. (1971) · Archives of Internal Medicine · doi:10.1001/archinte.1971.00310130120021 · Cited by 157 · see citing works
MODULATION OF NORADRENALINE RELEASE THROUGH ACTIVATION OF PRESYNAPTIC β‐ADRENORECEPTORS
Majewski, H. (1983) · Journal of Autonomic Pharmacology · doi:10.1111/j.1474-8673.1983.tb00496.x · Cited by 153 · see citing works
Weber, M. A., Jamerson, K., Bakris, G. L., Weir, M. R., Zappe, D., Zhang, Y., Dahlof, B., Velazquez, E. J., & Pitt, B. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61343-9 · Cited by 150 · see citing works
Relation of Low Body Mass to Death and Stroke in the Systolic Hypertension in the Elderly Program
Wassertheil-Smoller, S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.494 · Cited by 144 · see citing works
Is hypertension more benign when associated with obesity?
Barrett-Connor, E., & Khaw, K. T. (1985) · Circulation · doi:10.1161/01.cir.72.1.53 · Cited by 141 · see citing works
Alvarenga, M. E., Richards, J. C., Lambert, G., & Esler, M. D. (2006) · Psychosomatic Medicine · doi:10.1097/01.psy.0000195872.00987.db · Cited by 136 · see citing works
Self-citationThe Relationship between Vascular Function and the Autonomic Nervous System
Amiya, E., Watanabe, M., & Komuro, I. (2014) · Annals of Vascular Diseases · doi:10.3400/avd.ra.14-00048 · Cited by 129 · see citing works
Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans
Esler, M. D., Wallin, G., Dorward, P. K., Eisenhofer, G., Westerman, R., Meredith, I., Lambert, G., Cox, H. S., & Jennings, G. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.260.4.r817 · Cited by 124 · see citing works
Self-citationContrasting clinical properties and exercise responses in obese and lean hypertensive patients
Weber, M. A., Neutel, J. M., & Smith, D. H. G. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01103-7 · Cited by 122 · see citing works
Lambert, É., Dawood, T., Straznicky, N. E., Sari, C. I., Schlaich, M. P., Esler, M., & Lambert, G. W. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283350ea4 · Cited by 120 · see citing works
Self-citationFerrier, C. P., Jennings, G., Eisenhofer, G., Lambert, G. W., Cox, H. S., Kalff, V., Kelly, M., & Esler, M. (1993) · Journal of Hypertension · doi:10.1097/00004872-199311000-00009 · Cited by 114 · see citing works
Self-citationNILSSON, H., LJUNG, B., SjÖBLOM, N., & Wallin, B. G. (1985) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1985.tb07592.x · Cited by 114 · see citing works
Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes
Goldstein, D. S., Holmes, C. S., Frank, S. M., Dendi, R., Cannon, R. O., Sharabi, Y., Esler, M., & Eisenhofer, G. (2002) · Circulation · doi:10.1161/01.cir.0000036015.54619.b6 · Cited by 114 · see citing works
Self-citationEsler, M., Dudley, F., Jennings, G., Debinski, H. S., Lambert, G. W., Jones, P., Crotty, B. J., Colman, J. C., & Willett, I. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-446 · Cited by 112 · see citing works
Self-citationEffects of aging on epinephrine secretion and regional release of epinephrine from the human heart
Esler, M., Kaye, D. M., Thompson, J., Jennings, G., Cox, H. S., Turner, A., Lambert, G. W., & Seals, D. R. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852502 · Cited by 110 · see citing works
Self-citationDepression—A Cardiac Risk Factor in Search of a Treatment
Frasure‐Smith, N. (2003) · JAMA · doi:10.1001/jama.289.23.3171 · Cited by 99 · see citing works
Macefield, V. G., Rundqvist, B., Sverrisdóttir, Y. B., Wallin, B. G., & Elam, M. (1999) · Circulation · doi:10.1161/01.cir.100.16.1708 · Cited by 96 · see citing works
Phenotypic Evidence of Faulty Neuronal Norepinephrine Reuptake in Essential Hypertension
Rumantir, M. S., Kaye, D. M., Jennings, G. L., Vaz, M., Hastings, J. A., & Esler, M. D. (2000) · Hypertension · doi:10.1161/01.hyp.36.5.824 · Cited by 95 · see citing works
Self-citationLambert, E., Eikelis, N., Esler, M., Dawood, T., Schlaich, M., Bayles, R., Socratous, F., Agrotis, A., Jennings, G., Lambert, G., et al. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.750471 · Cited by 94 · see citing works
Self-citationLambert, É., Straznicky, N. E., Sari, C. I., Eikelis, N., Hering, D., Head, G. A., Dixon, J. B., Esler, M., Schlaich, M. P., & Lambert, G. W. (2012) · American Journal of Hypertension · doi:10.1093/ajh/hps016 · Cited by 79 · see citing works
Self-citationPossible genetic influence on the strength of human muscle nerve sympathetic activity at rest.
Wallin, B. G., Kunimoto, M., & Sellgren, J. (1993) · Hypertension · doi:10.1161/01.hyp.22.3.282 · Cited by 76 · see citing works
‘Obesity paradox’ misunderstands the biology of optimal weight throughout the life cycle
Dixon, J. B., Egger, G. J., Finkelstein, E. A., Kral, J. G., & Lambert, G. W. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.59 · Cited by 72 · see citing works
Self-citationRumantir, M. S., Jennings, G. L., Lambert, G. W., Kaye, D. M., Seals, D. R., & Esler, M. D. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018060-00009 · Cited by 72 · see citing works
Self-citationGoldstein, D. S., Horwitz, D., Keiser, H. R., Polinsky, R. J., & Kopin, I. J. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111134 · Cited by 71 · see citing works
Kidney-Induced Hypertension Depends on Superoxide Signaling in the Rostral Ventrolateral Medulla
Oliveira‐Sales, E. B., Colombari, D. S. A., Davisson, R. L., Kasparov, S., Hirata, A. E., Campos, R. R., & Paton, J. F. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.150425 · Cited by 71 · see citing works
Single‐unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover
Lambert, E. A., Schlaich, M. P., Dawood, T., Sari, C., Chopra, R., Barton, D. A., Kaye, D. M., Elam, M., Esler, M. D., & Lambert, G. W. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.205351 · Cited by 68 · see citing works
Self-citationPanic disorder: coronary spasm as a basis for cardiac risk?
Mansour., V. M., Thompson, J. M., Esler, M., Wilkinson, D. J. C., Jennings, G., & Schwarz, R. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb138992.x · Cited by 66 · see citing works
Self-citationElam, M., McKenzie, D., & Macefield, V. G. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00899.2001 · Cited by 63 · see citing works
Sverrisdóttir, Y. B., Jansson, L. M., Hägg, U., & Gan, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009257 · Cited by 58 · see citing works
Scott, W. F. (1982) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2981444 · Cited by 58 · see citing works
Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, nonneural release
Kaye, D. M., Lefkovits, J., Cox, H. S., Lambert, G. W., Jennings, G., Turner, A., & Esler, M. (1995) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1995.269.1.h182 · Cited by 57 · see citing works
Self-citationRenal denervation for treatment of drug-resistant hypertension
Esler, M. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.09.014 · Cited by 55 · see citing works
Self-citationEisenhofer, G., Smolich, J. J., Cox, H. S., & Esler, M. (1991) · Circulation · doi:10.1161/01.cir.84.3.1354 · Cited by 54 · see citing works
Self-citationBlunted norepinephrine responsiveness to changing energy states in obese subjects
Bazelmans, J., Nestel, P. J., O'Dea, K., & Esler, M. D. (1985) · Metabolism · doi:10.1016/0026-0495(85)90125-8 · Cited by 52 · see citing works
Self-citationMarques, F. Z., Eikelis, N., Bayles, R., Lambert, É., Straznicky, N. E., Hering, D., Esler, M., Head, G. A., Barton, D. A., Schlaich, M. P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.40 · Cited by 51 · see citing works
Self-citationKaplon, R. E., Walker, A. E., & Seals, D. R. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00721.2011 · Cited by 45 · see citing works
Lambert, E., Dawood, T., Schlaich, M., Straznicky, N., Esler, M., & Lambert, G. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04905.x · Cited by 44 · see citing works
Self-citationThe sympathetic nervous system and atherosclerosis
Lichtor, T., Davis, H. R., Johns, L., Vesselinovitch, D., Wissler, R. W., & Mullan, S. M. (1987) · Journal of neurosurgery · doi:10.3171/jns.1987.67.6.0906 · Cited by 44 · see citing works
Fat‐free mass loss generated with weight loss in overweight and obese adults: what may we expect?
Dixon, J. B., Lambert, E. A., Grima, M., Rice, T., Lambert, G. W., & Straznicky, N. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12389 · Cited by 40 · see citing works
Self-citationThe Effect of Moxonidine on Endothelial Dysfunction in Metabolic Syndrome
Topal, E., Çıkım, A. S., Çıkım, K., Temel, İ., & Оздемир, Р. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606050-00007 · Cited by 40 · see citing works
Catheter ablation for atrial fibrillation: Should it be first-line therapy?
Wharton, J. M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.017 · Cited by 40 · see citing works
Ganglionic transmission in a vasomotor pathway studied <i>in vivo</i>
Bratton, B., Davies, P., Jänig, W., & McAllen, R. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2009.185025 · Cited by 38 · see citing works
NET silencing by let-7i in postural tachycardia syndrome
Khan, A. W., Ziemann, M., Corcoran, S. J., Kaipananickal, H., Okabe, J., Rafehi, H., Maxwell, S., Esler, M., & El‐Osta, A. (2017) · JCI Insight · doi:10.1172/jci.insight.90183 · Cited by 37 · see citing works
Self-citationInsulin and the sympathetic nervous system in the pathophysiology of hypertension.
Landsberg, L. (1996) · PubMed · Cited by 33 · see citing works
Modulation of Catecholamine‐Synthesizing Enzymes in the Rat Heart by Repeated Immobilization Stress
Mičutková, L., KREPSOVA, K., Sabban, E. L., Križanová, O., & Květňanský, R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.052 · Cited by 29 · see citing works
Straznicky, N. E., Lambert, E. A., Grima, M. T., Eikelis, N., Richards, K., Nestel, P. J., Dawood, T., Masuo, K., Sari, C. I., Dixon, J. B., et al. (2014) · Obesity · doi:10.1002/oby.20614 · Cited by 21 · see citing works
Self-citationShah, R. V., Abbasi, S. A., Yamal, J., Davis, B. R., Barzilay, J., Einhorn, P. T., Goldfine, A., & the ALLHAT Collaborative Research Group (2014) · The Journal of Clinical Hypertension · doi:10.1111/jch.12325 · Cited by 21 · see citing works
KIMURA, S., MIURA, Y., ADACHI, M., ADACHA, M., NEZU, M., TORIYABE, S., SUGAWARA, T., ISHIZUKA, Y., NOSHIRO, T., TAKAHASHI, M., et al. (1983) · Japanese Circulation Journal · doi:10.1253/jcj.47.1232 · Cited by 17 · see citing works
Ando, S.-I., Imaizumi, T., & Takeshita, A. (1993) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(93)90054-x · Cited by 17 · see citing works
Thompson, J. M., Wallin, B. G., Lambert, G. W., Jennings, G., & Esler, M. (1998) · Clinical Science · doi:10.1042/cs0940383 · Cited by 17 · see citing works
Self-citationBMI, age, and mortality: the slaying of a beautiful hypothesis by an ugly fact
Sorkin, J. D. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.084780 · Cited by 16 · see citing works
Angiotensin II, Oxidant Signaling, and Hypertension
Davisson, R. L., & Zimmerman, M. C. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.144477 · Cited by 15 · see citing works
The obesity-mortality association: where is the nadir of the U-shaped curve?
Andrés, R. (1980) · PubMed · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654 · see citing works
Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited
da Silva, A. A., do Carmo, J. M., Li, X., Wang, Z., Mouton, A. J., & Hall, J. E. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.066 · Cited by 381 · see citing works
Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases
Balasubramanian, P., Hall, D., & Subramanian, M. (2018) · GeroScience · doi:10.1007/s11357-018-0048-5 · Cited by 109 · see citing works
Visaria, A., & Setoguchi, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287218 · Cited by 81 · see citing works
Device-Based Neuromodulation for Resistant Hypertension Therapy
Lohmeier, T. E., & Hall, J. E. (2019) · Circulation Research · doi:10.1161/circresaha.118.313221 · Cited by 71 · see citing works
Chrysant, S. G., & Chrysant, G. S. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1568019 · Cited by 70 · see citing works
Esler, M., Lambert, G. W., Esler, D., Sari, C. I., Guo, L. J., & Jennings, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002407 · Cited by 57 · see citing works
Self-citationCentral and peripheral sympathetic activation in heart failure
Grassi, G. M., Mancia, G., & Esler, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab222 · Cited by 56 · see citing works
Self-citationSympathetic activation in congestive heart failure: an updated overview
Grassi, G. M., Quarti‐Trevano, F., & Esler, M. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09901-2 · Cited by 54 · see citing works
Self-citationLi, R., Liu, Y., Wu, J., Chen, X., Lu, Q., Xia, K., Liu, C., Sui, X. Y., Liu, Y., Wang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202400426 · Cited by 44 · see citing works
Spallone, V., & Valensi, P. E. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101224 · Cited by 43 · see citing works
Impact of sex and age on metabolism, sympathetic activity, and hypertension
Yoo, J., & Fu, Q. (2020) · The FASEB Journal · doi:10.1096/fj.202001006rr · Cited by 37 · see citing works
Obesity, Hypertension, and Bariatric Surgery
Samson, R., Ayinapudi, K., Jemtel, T. H. L., & Oparil, S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01049-x · Cited by 37 · see citing works
Obesity, Systemic Hypertension, and Pulmonary Hypertension: A Tale of Three Diseases
Wahab, A., Dey, A. K., Bandyopadhyay, D., Katikineni, V. S., Chopra, R., Vedantam, K., Devraj, M., Chowdary, A. K., Navarengom, K., Lavie, C. J., et al. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100599 · Cited by 30 · see citing works
Central mechanisms in sympathetic nervous dysregulation in obesity
Patel, M., Braun, J., Lambert, G. W., Kameneva, T., Keatch, C., & Lambert, É. (2023) · Journal of Neurophysiology · doi:10.1152/jn.00254.2023 · Cited by 33 · see citing works
Self-citationSympathetic Pathophysiology in Hypertension Origins: The Path to Renal Denervation
Esler, M., Osborn, J. W., & Schlaich, M. P. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.21715 · Cited by 25 · see citing works
Self-citationBody Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial
Oxlund, C. S., Pareek, M., Rasmussen, B. S., Vaduganathan, M., Biering‐Sørensen, T., Byrne, C., Almarzooq, Z., Olsen, M. H., & Bhatt, D. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.024 · Cited by 23 · see citing works
Esler, M. (2021) · Autonomic Neuroscience · doi:10.1016/j.autneu.2021.102925 · Cited by 22 · see citing works
Self-citationEsler, M., Kjeldsen, S. E., Pathak, A., Grassi, G. M., Kreutz, R. H., & Mancia, G. (2022) · Blood Pressure · doi:10.1080/08037051.2022.2110858 · Cited by 22 · see citing works
Self-citationAssociation of BMI, comorbidities and all-cause mortality by using a baseline mortality risk model
Li, J., Simon, G., Castro, M. R., Kumar, V., Steinbach, M. S., & Caraballo, P. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253696 · Cited by 21 · see citing works
Waragai, M., Ho, G. J., Takamatsu, Y., Shimizu, Y., Sugino, H., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.009 · Cited by 19 · see citing works
Liu, L., Shen, G., Huang, J., Yu, Y., Chen, C., Huang, Y., & Feng, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1105-5 · Cited by 20 · see citing works
Pulse wave velocity is decreased with obesity in an elderly Chinese population
Yang, H., Zhao, J., Deng, X., Tan, I., Butlin, M., Avolio, A. P., & Zuo, J. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13659 · Cited by 18 · see citing works
Changes in hemodynamics associated with metabolic syndrome are more pronounced in women than in men
Kangas, P., Tikkakoski, A., Kettunen, J., Eräranta, A., Huhtala, H., Kähönen, M. A. P., Sipilä, K., Mustonen, J. T., & Pörsti, I. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-54926-0 · Cited by 15 · see citing works
Zhu, J., Liu, X., Zhang, J., Li, J., Chen, L., Huang, C., Li, J., Yu, Y., Xu, H., & Qin, G. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00994-0 · Cited by 14 · see citing works
Hsu, J., Yang, Y., Chuang, S.-L., Chung, Y., Wang, C., & Lin, L. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01415-2 · Cited by 13 · see citing works
Carving the senescent phenotype by the chemical reactivity of catecholamines: An integrative review
Golubev, A. G. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101570 · Cited by 12 · see citing works
Yan, J., Li, X., Long, W., Yuan, T., & Xian, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.855650 · Cited by 11 · see citing works
Esler, M., Alvarenga, M. E., Barton, D., Jennings, G., Kaye, D. M., Guo, L. J., Schwarz, R., & Lambert, G. W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.818012 · Cited by 10 · see citing works
Self-citationThe Association between Antihypertensive Medication Use and Blood Pressure Is Influenced by Obesity
Parikh, J. S., Randhawa, A. K., Wharton, S., Edgell, H., & Kuk, J. L. (2018) · Journal of Obesity · doi:10.1155/2018/4573258 · Cited by 10 · see citing works
Chen, B., Somers, V. K., Tang, X., & Li, Y. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s297707 · Cited by 9 · see citing works
Zhang, Y., Zheng, Q., Dai, X., Xu, X., & Ma, L. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2824 · Cited by 9 · see citing works
Gavaldà-Manso, M., Jiménez‐Marrero, S., Cainzos‐Achirica, M., Garay, A., Enjuanes, C., Yun, S., Díez‐López, C., González‐Costello, J., Tajes, M., Farré, N., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.094 · Cited by 9 · see citing works
Liao, J., Qiu, M., Li, J., Li, Y., & Han, Y. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14953 · Cited by 8 · see citing works
Sympathetic Activation in Essential Hypertension: Understanding the Toxic Trifecta
Esler, M. (2018) · Heart Lung and Circulation · doi:10.1016/s1443-9506(18)30002-7 · Cited by 8 · see citing works
Self-citationMatsuki, H., Genma, T., Mandai, S., Fujiki, T., Mori, Y., Ando, F., Mori, T., Susa, K., Iimori, S., Naito, S., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21880 · Cited by 7 · see citing works
Pei, J., Wang, X., Zheng, K., Su, W., & Hu, X. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003088 · Cited by 7 · see citing works
Tlegenova, Z. S., Zholdin, B., Kudaiberdieva, G. Z., & Abdrakhmanov, A. S. (2019) · Kardiologiia · doi:10.18087/cardio.2617 · Cited by 6 · see citing works
Yang, D., Ye, S., Zhang, K., Huang, Z., & Zhang, L. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03179-x · Cited by 5 · see citing works
Barillas-Lara, M. I., Faaborg-Andersen, C. C., Quintana, R. A., Loro-Ferrer, J. F., Mandras, S. A., & daSilva‐deAbreu, A. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001069 · Cited by 5 · see citing works
Obesity is bad regardless of the obesity paradox for hypertension and heart disease
Chrysant, S. G. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13281 · Cited by 5 · see citing works
Chobufo, M. D., Rahman, E. U., Farah, F., Suliman, M., Mansoor, K., Elhamdani, A., El-Hamdani, M. O., & Balla, S. (2020) · International Journal of Cardiology Hypertension · doi:10.1016/j.ijchy.2020.100066 · Cited by 4 · see citing works
Fan, Y., Liu, J., Jin, L., Liu, Z., Han, L., Wang, Y., Zhang, Y., Shen, P., & Li, Z. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02954-6 · Cited by 4 · see citing works
Faber, J., Milanez, M. I. O., Simões, C. S., & Campos, R. R. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1176634 · Cited by 4 · see citing works
He, F., Zhou, Z., Zhao, S., Li, W., Lian, X., Yu, J., Lin, Z., Song, Z., Chen, W., & Li, J. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25118 · Cited by 3 · see citing works
A modern view on the prevention and treatment of arterial hypertension in obesity
Молчанова, О. В. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212406197 · Cited by 3 · see citing works
Yue, Z., Qian, L., Jin, Y., Xia, Y., Sha, H., Wu, Q., & Hu, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s411440 · Cited by 3 · see citing works
Chen, B., Chen, L., Dai, Y., Wu, J., Zheng, D., Vgontzas, A. N., Tang, X., & Li, Y. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.05.050 · Cited by 3 · see citing works
Intensive Blood Pressure Control and Body Size
HENDREN, N. S., Neeland, I. J., Vongpatanasin, W., Kumbhani, D. J., Drazner, M. H., Tang, W. H. W., & Grodin, J. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.058 · Cited by 3 · see citing works
Coffee drinking then and now: research continues to better understand this ubiquitous beverage
Esler, M. (2023) · Clinical Autonomic Research · doi:10.1007/s10286-023-00981-7 · Cited by 3 · see citing works
Self-citationJarrett, M. S., Anderson, T., Wideman, L., & Davis, P. G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303117 · Cited by 1 · see citing works
Celebrating 40 Years of Accomplishments
Dominiczak, A. F., Kuo, D., Bhalla, V., Granger, J. P., & Griffin, K. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.12252
Panic disorder: Autonomic nervous mechanisms of risk
Esler, M., Lambert, G. W., Kaye, D. M., Lambert, É., Esler, R. O., Guo, L. J., & Alvarenga, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85492-4.00182-4
Self-citationHönemann, J., & Jordan, J. (2024) · Hypertension Research · doi:10.1038/s41440-023-01560-z
Characterisation of neurogenic lipolytic responses in white adipose tissue ex vivo
Goddard, K. E., & Fountain, S. J. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17445
Fan, Y., Liu, J., Jin, L., Liu, Z., Han, L., Wang, Y., Zhang, Y., Shen, P., & Li, Z. (2022) · Figshare · doi:10.6084/m9.figshare.21629196
Yang, D., Ye, S., Zhang, K., Huang, Z., & Zhang, L. (2023) · Figshare · doi:10.6084/m9.figshare.22623389
Fan, Y., Liu, J., Jin, L., Liu, Z., Han, L., Wang, Y., Zhang, Y., Shen, P., & Li, Z. (2022) · Figshare · doi:10.6084/m9.figshare.21629193
Hsu, J.-C., Yang, Y.-Y., Chuang, S.-L., Chung, Y.-W., Wang, C.-H., & Lin, L.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.17079568
ZEMB, P. A., & Joulia, F. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6068352
- Authors
- Esler, M., Lambert, G., Schlaich, M., Dixon, J., Sari, C. I., & Lambert, E.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- From the Baker Heart and Diabetes Institute, Melbourne, Australia (M.E., J.D., C.I.S.); Swinburne University of Technology, Melbourne, Australia (G.L., E.L.); and School of Medicine, Royal Perth Hospital Unit, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Perth (M.S.).
- Venue
- Hypertension
- Published
- 2018-01
- Volume
- 71
- Issue
- 1
- Pages
- 22-33
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2770121686
- Semantic Scholar
- 5b84cbb3f471e879e70742f2e63f94a7a41cdbd8
- Cited by
- 60
- References
- 117
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 7 · 2023: 10 · 2022: 8 · 2021: 10 · 2020: 6 · 2019: 9 · 2018: 8
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Funders
- Australian Government
- Swinburne University of Technology
- State Government of Victoria
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- obesity paradox, obesity, cardiovascular risk
- MeSH terms
- Humans, Hypertension, Mortality, Obesity, Sympathetic Nervous System, Comorbidity, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review